Home Newsfeeds JMP Securities Downgrades Squarespace to Market Perform

JMP Securities Downgrades Squarespace to Market Perform

JMP Securities analyst Andrew Boone downgrades Squarespace (NYSE:SQSP) from Market Outperform to Market Perform.

byBenzinga Newsdesk

July 14, 2022

1 minute read

JMP Securities analyst Andrew Boone downgrades Squarespace (NYSE:SQSP) from Market Outperform to Market Perform.

Fortinet’s Mixed Q3 Results Sends Stock Falling After-Hours – Here’s Why

By Ryan Gustafson

November 2, 4:28 PM

Fortinet, Inc. (NASDAQ: FTNT) shares are trading lower in Thursday's after-hours session following the company's third-quarter financial results.

FTNT

Hewlett Packard Enterprise Delivers Second Exascale Supercomputer, Aurora, to US Department of Energy’s Argonne National Laboratory

By Benzinga Newsdesk

May 13, 5:11 AM

Today at ISC High Performance 2024,Hewlett Packard Enterprise (NYSE:HPE) announced that it has delivered the world's second exascale supercomputer, Aurora, in collaboration with Intel for the United States

HPE

Matson Announces Preliminary Q4 Results, Provides Business Update; Sees Q4 EPS $1.65-$1.78; Net Income $57.7M-$62.2M

By Benzinga Newsdesk

January 18, 5:12 PM

Expects 4Q23 operating income for Ocean Transportation to be $61.0 to $66.0 millionExpects 4Q23 operating income for Logistics to be $8.0 to $9.0 millionExpects 4Q23 net income and diluted EPS to be $57.7 to

MATX

Why Are BioXcel Therapeutics Shares Plummeting Today

By Vandana Singh

June 29, 10:16 AM

BioXcel Therapeutics Inc (NASDAQ: BTAI) shares are tumbling after the company released topline results for TRANQUILITY II, a Phase 3 trial of BXCL501 for the acute treatment of

BTAI

JMP Securities Downgrades Squarespace to Market Perform

Related Posts

Fortinet’s Mixed Q3 Results Sends Stock Falling After-Hours – Here’s Why

Hewlett Packard Enterprise Delivers Second Exascale Supercomputer, Aurora, to US Department of Energy’s Argonne National Laboratory

Matson Announces Preliminary Q4 Results, Provides Business Update; Sees Q4 EPS $1.65-$1.78; Net Income $57.7M-$62.2M

Why Are BioXcel Therapeutics Shares Plummeting Today